601162 Tianfeng
- 4.19
- +0.21+5.28%
Tianfeng News
Tianfeng: Maintaining SMOORE INTL's "Buy" rating and being bullish on the growth potential of the HNB new business.
Tianfeng released a research report stating that, based on the company's Technology and leading advantages, it maintains a "Buy" rating for SMOORE INTL (06969), expecting the company's Net income for 2024-2026 to be 1.609/1.966/2.494 billion yuan, with year-on-year changes of -2.19%/+22.19%/+26.85%. The firm believes that as a global leader in providing atomization Technology solutions, the company's barrier advantages are becoming more pronounced, and under the backdrop of increasingly stringent regulations, the concentration of the Industry Chain is expected to accelerate. Tianfeng's main points are as follows: the company released a revised announcement of the Stock-based Incentive plan, with performance objectives...
Tianfeng: Maintain KUAISHOU-W 'Buy' rating and suggest keeping an eye on the company's profit margin changes.
Tianfeng published a research report stating that, considering the advertising growth of KUAISHOU-W (01024) exceeds expectations, the company is projected to have revenues of 127.1/140.7 billion yuan for 2024-2025; the firm expects the company's adjusted net income for 2024-2025 to be 17.6/21.6 billion yuan, maintaining a "Buy" rating. In Q3 2024, the company achieved revenues of 31.1 billion yuan, with adjusted net income of 3.9 billion yuan and gross profit of 16.9 billion yuan. The firm believes the company's core business revenue is growing steadily and recommends continuous attention to changes in the company's profit margins. Tianfeng's main points are as follows: Flow
Tianfeng Securities Co., Ltd. (SHSE:601162) Stock Most Popular Amongst Retail Investors Who Own 59%, While Private Companies Hold 27%
Tianfeng: Maintain CTIHK's "Buy" rating, expected to become a direct beneficiary of Industry development and transformation.
Tianfeng released a research report stating that it maintains a "Buy" rating for CTIHK (06055), believing that the company, backed by the China Tobacco Group, has significant competitive advantages. It is currently the only overseas capital operation and international business expansion platform under China Tobacco, making it a rare entity and expected to become a direct beneficiary of the development and transformation of the Tobacco industry in China. The company forecasts its net income for 2024/25/26 to be 0.787/0.91/1.1 billion Hong Kong dollars; the company is the only international business platform within the China Tobacco system. The company issued a positive profit forecast, expecting that the profit attributable to owners for the full year of 2024 will increase by no less than 30% year-on-year.
Tianfeng Securities: Initiating coverage with a "Buy" rating for Chabaidao.
Recently, Tianfeng Securities initiated coverage on Cha Baidao (02555), assigning it a "Buy" rating. The report states that in terms of product capability, Cha Baidao's product matrix combines classic and seasonal limited products, leading the market with high cost performance; in terms of business model, the company's main source of income is from franchising, aiming for a more stable revenue source. Due to strict selection, only about 7% of candidates can become franchisees; in terms of supply chain, Cha Baidao continues to invest in supply chain construction. The firm expects that as supply chain efficiency improves and transportation costs are optimized, material costs will be effectively controlled, enhancing Cha Baidao's future gross profit.
Tianfeng: Maintains YUE YUEN IND ‘Buy’ rating with positive growth continuing in manufacturing in November.
Tianfeng released a research report stating that it maintains a "Buy" rating for YUE YUEN IND (00551), expecting the company's revenue for FY24-26 to be $8.65/9.65/10.94 billion, respectively; net profit attributable to parent company is expected to be $0.46/0.54/0.62 billion, respectively; and corresponding EPS is expected to be $0.28/0.33/0.38 per share, respectively. The company's revenue in November 2024 was $0.68 billion, a year-on-year increase of 7.5%, with cumulative revenue of $7.5 billion, a year-on-year increase of 3.4%. The main points from Tianfeng are as follows: The company released November data indicating that revenue from its manufacturing business in 2024 saw a year-on-year growth.
tianfeng Securities: Initiates Coverage on Kelun Botai Biomedical-B with a "shareholding" rating. Enhanced Commercialization Certainty.
Tianfeng released a research report stating that it has initiated coverage of Kelun Biotechnology-B (06990) with a "shareholding" rating. It forecasts the company's revenue for 2024-2026 to be 1.217 billion yuan, 1.654 billion yuan, and 2.476 billion yuan respectively; the net income attributable to the parent company is expected to be -0.72 billion yuan, -0.606 billion yuan, and -0.415 billion yuan. Considering the company's advantages in the ADC technology platform, substantial market space for core products, and promising overseas prospects, the company is viewed as bullish for development. The main viewpoints from Tianfeng are as follows: the ADC self-research capabilities are outstanding, with global research being advanced by Merck, and the certainty of commercialization is strengthened.
Tianfeng Securities: Ideal autos - W3-4Q fundamentals are gradually trending upwards with the expectation of recovery. The continuous improvement of store and infrastructure layout.
Tianfeng Securities released a research report stating that the bank believes that extreme emotions of concern about domestic consumption at the trade level have been digested in Q3. In fact, auto consumption saw a slight recovery in July driven by the policies of replacing old cars with new ones. The continuity of market demand thereafter is indeed difficult to determine, but the underlying fundamentals of Ideal Auto-W (02015) are expected to gradually improve in 3-4Q, and the bank predicts that the development of smart driving technology is expected to drive growth in vehicle value/gross margin.
Tianfeng Securities: Maintains a "buy" rating on China Longyuan, with asset injection helping to boost installed capacity growth.
Tianfeng Securities issued a research report stating that it maintains a 'buy' rating on China Longyuan (00916), with forecasted net income attributable to the parent company in 2024-2026 of 6.6, 7.5, and 8.2 billion yuan. The company announced its performance for the third quarter of 2024. In the first three quarters, the company achieved a revenue of 26.35 billion yuan, a year-on-year decrease of 6.37%; and a net income attributable to the parent company of 5.668 billion yuan, a year-on-year decrease of 11.38%. The main points from Tianfeng Securities are as follows: the equity of Jiangyin Sulong has been transferred, with a year-on-year increase of 2.4% in power generation for the first three quarters. The equity of Jiangyin Sulong Thermoelectric Co., Ltd. has been transferred, reducing the controlled installed capacity by 1.24 GW.
msci chinese index adjustment announced! 4 new constituent stocks including Chuantou Energy (601136.SH)
On November 7th, the international index compilation company MSCI announced the index quarterly adjustment results for November 2024, which will take effect after the market closes on November 25, 2024.
tianfeng Securities (601162.SH): The company has no assets restructuring plan.
GE Longhui November 6th, tianfeng Securities (601162.SH) stated on the interactive platform that the company has no asset restructuring plan or other significant matters that should be disclosed but have not been disclosed.
Tianfeng Securities (601162.SH): The company does not have a localized debt business for AMC.
November 5, Geelonghui | Tianfeng Securities (601162.SH) stated on the interactive platform that the company does not have localized AMC debt business. Details of the company's main business can be found in the company's disclosed quarterly reports.
Tianfeng Securities: Tianfeng Securities Co., Ltd. Report for the Third Quarter of 2024
Tianfeng Securities Co., Ltd. Third Quarter Report 2024
Tianfeng Securities: maintains a 'buy' rating on Era Angel, with strong overseas business growth.
Tianfeng Securities released research reports stating that it maintains a 'buy' rating on SITC Technology (06699), with expected revenue of 1.776/2.184/2.685 billion yuan and expected net income attributable to mother of 0.07/0.156/0.269 billion yuan for the years 2024-2026. It is reported that the company's 2024 interim report showed revenue of 0.862 billion yuan, a 39.8% year-on-year increase; and net income attributable to mother of 22.479 million yuan, a 30.4% year-on-year decrease. In particular, the china market achieved revenue of 0.633 billion yuan, a 10% year-on-year increase.
tianfeng (601162.SH): There is no plan for merger and reorganization or other significant matters that should be disclosed but have not been disclosed.
Gelonghui October 16th | tianfeng Securities (601162.SH) stated on the interactive platform that the company does not have any merger and reorganization plans or other significant undisclosed matters that should be disclosed.
tianfeng Securities: Maintains a "buy" rating on 361 degrees, with online growth leading in Q3 24.
Tianfeng Securities released a research report stating that it maintains a 'buy' rating on 361 degrees (01361), expecting the company's revenue in 2024 and 2025 to be 10.09 billion RMB, 11.69 billion RMB, and 13.45 billion RMB respectively; net profit attributable to shareholders to be 1.11 billion RMB, 1.29 billion RMB, and 1.53 billion RMB respectively; corresponding EPS to be 0.54 RMB/share, 0.62 RMB/share, and 0.74 RMB/share. Tianfeng Securities' main points are as follows: In Q3 2024, 361 degrees' offline main brand retail performance was good, with a year-on-year growth of about 10%.
Tianfeng: Maintaining a "buy" rating on chow tai fook. Continued rise in gold prices may temporarily hinder consumer enthusiasm.
Tianfeng Securities released research reports stating that they maintain a "buy" rating on Chow Tai Fook (01929), as the strong performance of gold prices affects gold jewelry consumption. At the same time, the optimization of gross margin with the increase in the proportion of fixed-price products, adjusting the company's profit forecast. It is expected that the revenue for FY25-27 will be 94.5 billion Hong Kong dollars, 103.9 billion Hong Kong dollars, and 114.5 billion Hong Kong dollars respectively (previously 113.6 billion Hong Kong dollars, 121.4 billion Hong Kong dollars, 130.3 billion Hong Kong dollars), and the net profit attributable to owners will be 5.98 billion Hong Kong dollars, 6.91 billion Hong Kong dollars, 7.94 billion Hong Kong dollars (previously 6.9 billion Hong Kong dollars, 7.6 billion Hong Kong dollars, 8.5 billion Hong Kong dollars); EPS will be 0.60 Hong Kong dollars.
Tianfeng Securities: Innovent Bio's 2024 interim report meets expectations, maintaining a "buy" rating.
Tianfeng Securities released a research report stating that they maintain a 'buy' rating for Innovent Bio (01801), considering the continuous increase in sales volume of the company's listed products, and multiple R&D pipelines are expected to enter the product harvest period. The revenue expectations for 2024 and 2025 have been raised from 7.225 billion yuan and 9.193 billion yuan to 7.97 billion yuan and 10.235 billion yuan respectively. It is estimated that the revenue in 2026 will reach 13.143 billion yuan. At the same time, the company's net income for 2024 and 2025 has been adjusted from -0.766 billion yuan and -0.17 billion yuan to -0.756 billion yuan and 0.089 billion yuan, with an estimated net income of 10.0 billion yuan in 2026.
The selected announcement from Gelunhui: Will Semiconductor: Net income in the first three quarters is expected to increase by 515.35% to 569.64% year-on-year; Tianfeng Securities: The company does not have any plans for merger and reorganization.
【Performance Data】Dongpeng Beverage (605499.SH): The net income is expected to increase by 57.04% to 64.89% year-on-year in the first three quarters. special treat Tianbang (002124.SZ): It is expected to make a profit of 1.301 billion yuan to 1.351 billion yuan in the first three quarters, turning losses compared to the same period last year. pacific shuanglin bio-pharmacy (000403.SZ): It is expected that the net income in the first three quarters will increase by 60% to 70% year-on-year. Shengnuo Biotechnology (688117.SH): It is expected that the net income in the first three quarters will increase by 43.9% to 75.88% year-on-year. Muyuan Foods (002714.SZ): It is expected to make a profit of 10 billion yuan to 11 billion yuan in the first three quarters.
No Data